Second-Line Treatment in Patients (pts) with Advanced Extra-Pulmonary Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC): A Systematic Review and Meta-Analysis

被引：0
|
作者：
McNamara, M. G. [1 ]
Frizziero, M. [2 ]
Jacobs, T. [2 ]
Lamarca, A. [2 ]
Hubner, R. [2 ]
Valle, J. W. [1 ]
Amir, E. [3 ]
机构：
[1] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
NEUROENDOCRINOLOGY | 2019年 / 108卷
关键词：
second-line therapy; neuroendocrine carcinoma; response rate; survival; extra-pulmonary;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
J12
引用
收藏
页码：188 / 188
页数：1
相关论文
共 50 条
  • [41] Regorafenib plus programmed death-1 inhibitors vs. regorafenib monotherapy in second-line treatment for advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Li, Zhao
    Wang, Jie
    Zhao, Jingbing
    Leng, Zhengwei
    ONCOLOGY LETTERS, 2024, 28 (01)
  • [42] Epidemiology of first- and second-line drugs-resistant pulmonary tuberculosis in Iran: Systematic review and meta-analysis
    Abbasian, Sara
    Heidari, Hamid
    Tadi, Danyal Abbasi
    Kardan-Yamchi, Jalil
    Taji, Asieh
    Darbandi, Atieh
    Asadollahi, Parisa
    Maleki, Abbas
    Kazemian, Hossein
    JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2024, 35
  • [43] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score
    Zhu, Andrew X.
    Baron, Ari David
    Malfertheiner, Peter
    Kudo, Masatoshi
    Kawazoe, Seiji
    Pezet, Denis
    Weissinger, Florian
    Brandi, Giovanni
    Barone, Carlo
    Okusaka, Takuji
    Wada, Yoshiyuki
    Park, Joon Oh
    Ryoo, Baek-Yeol
    Cho, Jae Yong
    Chung, Hyun Cheol
    Li, Chung-Pin
    Yen, Chia-Jui
    Lee, Kuan-Der
    Yang, Ling
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment A network meta-analysis
    Chen, Jianxin
    Wang, Junhui
    Xie, Fangwei
    MEDICINE, 2021, 100 (38)
  • [45] Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis
    Yu, Shi-Tong
    Ge, Jun-Na
    Luo, Jing-Yi
    Wei, Zhi-Gang
    Sun, Bai-Hui
    Lei, Shang-Tong
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 1525 - 1532
  • [46] Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Gu, Shuyan
    Hu, Xiaoqian
    Zhen, Xuemei
    Shi, Lizheng
    Shao, Hui
    Sun, Xueshan
    Gu, Yuxuan
    Huang, Minzhuo
    Dong, Hengjin
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [47] Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis
    Kanters, Steve
    Socias, Maria Eugenia
    Paton, Nicholas I.
    Vitoria, Marco
    Doherty, Meg
    Ayers, Dieter
    Popoff, Evan
    Chan, Keith
    Cooper, David A.
    Wiens, Matthew O.
    Calmy, Alexandra
    Ford, Nathan
    Nsanzimana, Sabin
    Mills, Edward J.
    LANCET HIV, 2017, 4 (10): : E433 - E441
  • [48] Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data
    Iacovelli, Roberto
    Santoni, Matteo
    Verzoni, Elena
    Grassi, Paolo
    Testa, Isabella
    de Braud, Filippo
    Cascinu, Stefano
    Procopiol, Giuseppe
    CLINICAL GENITOURINARY CANCER, 2015, 13 (02) : 137 - 141
  • [49] Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials
    Luo, Chengxin
    Huang, Xiangtao
    Wei, Ling
    Wu, Guixian
    Huang, Yarui
    Ding, Yaqun
    Huang, Zhen
    Chen, Jieping
    Li, Xi
    Zou, Yunding
    Xu, Shuangnian
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).
    McNamara, Mairead Geraldine
    Swain, Jayne
    Craig, Zoe
    Sharma, Rohini
    Faluyi, Olusola Olusesan
    Wadsley, Jonathan
    Morgan, Carys
    Wall, Lucy R.
    Chau, Ian
    Reed, Nick
    Sarker, Debashis
    Margetts, Jane
    Krell, Daniel
    Cave, Judith
    Sharmila, Sothi
    Anthoney, Alan
    Patel, Alkesh
    Lamarca, Angela
    Hubner, Richard
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 646 - 646
12345